Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes

Similar Items

• Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
  od: Nunoi, Kiyohide, i dr.
  Izdano: (2019)
• Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss
  od: Sato, Yuichi, i dr.
  Izdano: (2019)
• Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
  od: Tobe, Kazuyuki, i dr.
  Izdano: (2017)
• Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
  od: Matsubayashi, Yasuhiro, i dr.
  Izdano: (2021)
• Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
  od: Matsubayashi, Yasuhiro, i dr.
  Izdano: (2020)